CN105237466A - 一种合成三取代吡啶衍生物的方法 - Google Patents

一种合成三取代吡啶衍生物的方法 Download PDF

Info

Publication number
CN105237466A
CN105237466A CN201510699625.6A CN201510699625A CN105237466A CN 105237466 A CN105237466 A CN 105237466A CN 201510699625 A CN201510699625 A CN 201510699625A CN 105237466 A CN105237466 A CN 105237466A
Authority
CN
China
Prior art keywords
pyridine
phenyl
formula
bis
tolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510699625.6A
Other languages
English (en)
Other versions
CN105237466B (zh
Inventor
徐学锋
张旭
柳文敏
孙如中
闫彦磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang de st Digital Technology Co., Ltd.
Original Assignee
Nanyang Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Normal University filed Critical Nanyang Normal University
Priority to CN201510699625.6A priority Critical patent/CN105237466B/zh
Publication of CN105237466A publication Critical patent/CN105237466A/zh
Application granted granted Critical
Publication of CN105237466B publication Critical patent/CN105237466B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08Preparation by ring-closure
    • C07D213/09Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • C07D213/12Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

本发明提供了一种合成三取代吡啶衍生物的方法,属于吡啶衍生物的合成技术领域。一种合成三取代吡啶衍生物的方法,在三氟甲磺酸的存在下,由胺化合物和酮化合物反应合成吡啶衍生物,反应式如下:

Description

一种合成三取代吡啶衍生物的方法
技术领域
本发明属于吡啶衍生物的合成技术领域,具体涉及一种合成三取代吡啶衍生物的方法。
背景技术
吡啶类衍生物是一种重要的精细化工中间体,广泛应用于农药、医药橡胶助剂、表面活性剂、粘结剂和日用化工领域,随着人类社会的不断进步以及应用研究不断深入,对吡啶衍生物的需求量也急剧增加。因此,研究其新的、简单利于工业化的合成方法也十分必要,也必将产生较好的经济效益。
目前吡啶衍生物的合成方法尽管很多,然而,这些方法主要有气相法和液相法,却存在很大的局限性。例如,气相法是采用醋酸酸化乙醛,使乙醛聚合为三聚乙醛,然后同醋酸经过高压泵与氨水混合,反应需要高温(220~280℃)、高压(10~20MPa)。如果采用三氧化二铝为催化剂,反应需要的温度更高,达到500℃。目前气相法采用的其它催化剂产率,底物的适应性,反应条件很难同时满足社会需求。液相法包括醛酮-烯腈法、苄胺路线法和环戊二烯路线合成法等。但是这些方法也存在很多缺点:反应条件苛刻,反应温度高,有的需要高温高压,分离困难,反应的底物限制性较强,因此,利用一种方法合成吡啶衍生物很有限。另外,利用金属催化过程中,催化剂的活性有限,这些缺点造成制备过程的操作难度增加,危害操作人员健康,环境污染严重。然而,现有合成吡啶衍生物的方法普遍存在:需要活泼的反应底物、反应收率低、反应时间较长、副产物多难处理及反应的形式过于单一(导致所合成的产物有很大的局限性)以及反应过程需要大量的溶剂或金属催化剂等缺点。鉴于此,研发新颖、绿色环保的吡啶衍生物的制备方法显得尤为重要。
发明内容
本发明所要解决的技术问题是,针对现有技术的不足,提供一种操作简单,产率高,产物单一,便于分离和提纯的利用胺、酮衍生物合成吡啶衍生物的方法。
为解决上述技术问题,本发明所采用的技术方案是:
一种合成三取代吡啶衍生物的方法,在三氟甲磺酸(HOTf)的存在下,由式Ⅰ所示的胺化合物和式Ⅱ所示的酮化合物反应合成式Ⅲ所示的吡啶衍生物,
式Ⅰ:;式Ⅱ:;式Ⅲ:
其中,
R1选自苯基、甲苯基、噻吩基、苯甲基、C1-C7烷基中的一种,其中,R1取代基中的苯基、甲苯基、噻吩基、苯甲基、C1-C7烷基中的任何CH、CH2或CH3基团任选在所述CH、CH2或CH3基团上带有1、2或3个可相同或不同的以下的取代基:卤素或硝基;
R2选自苯基、甲苯基、噻吩基、苯并呋喃基、萘基中的一种,其中,R2取代基中的苯基、甲苯基、噻吩基、苯并呋喃基、萘基中的任何CH、CH2或CH3基团任选在所述CH、CH2或CH3基团上带有1、2或3个可相同或不同的以下的取代基:卤素或硝基;
卤素为氟、氯、溴或碘的取代基。
合成三取代吡啶衍生物的反应通式如下:
优选的,所述式Ⅰ所示的胺化合物为苄胺、对甲基苄胺、对氟苄胺、间甲基苄胺、间氟苄胺、2-噻吩甲胺、2-苯基乙胺或正己胺。
优选的,所述式Ⅱ所示的酮化合物为苯乙酮、对甲基苯乙酮、间甲基苯乙酮、2-乙酰基噻吩、2-乙酰基苯并呋喃、2-萘乙酮或对氯苯乙酮。
优选的,所述式Ⅲ所示的吡啶衍生物为2,6-二苯基-4-对甲基吡啶、4-(4-氟苯基)-2,6-二苯基吡啶、2,6-二苯基-4-间甲基吡啶、4-(3-氟苯基)-2,6-二苯基吡啶、2,6-苯基-4-(2-噻吩基)吡啶、4-苄基-2,6-二苯基吡啶、4-戊基-2,6-二苯基吡啶、4-戊基-2,6-二对甲苯基吡啶、4-戊基-2,6-二间甲苯基吡啶、4-苯基-2,6-二-(2-噻吩基)吡啶、2,6-二-(2-苯并呋喃)-4-苯基吡啶、2,6-二-(2-萘基)-4-对甲苯基吡啶、4-(4-氟苯基)-2,6-二-(2-萘基)吡啶、2,6-二-(4-氯苯基)-4-苯基吡啶、4-苯基-2,6-二对甲苯基吡啶、2,4,6-对甲苯基吡啶、4-(4-氟苯基)-2,6-二对甲苯基吡啶、2,4,6-三间甲基吡啶或4-(间氟苯基)-2,6-二间甲苯基吡啶。
优选的,所述合成三取代吡啶衍生物的方法,具体步骤如下:在反应容器中依次加入摩尔比为4:3的式Ⅰ所示的酮化合物和式Ⅱ所示的胺化合物,接着加入催化剂三氟甲磺酸,所述催化剂的加入量为0.05mmol/mmol酮化合物,在115~125℃油浴中反应18~24小时,冷却至室温,加水淬灭反应,萃取,减压浓缩,经柱层析纯化,得到三取代吡啶衍生物产品。
优选的,所述柱层析纯化的条件为:洗脱剂为石油醚和乙酸乙酯的混合物,石油醚和乙酸乙酯的体积比为50:1。
与现有技术相比,本发明的有益效果如下:本发明提供了一种利用胺、酮化合物在三氟甲磺酸的催化作用下合成吡啶衍生物的方法,该方法的反应底物易得,反应条件温和,无需高温高压处理,操作简便、安全,可高效地制备吡啶类化合物。本发明方法不仅能够适用于大量的官能团,而且操作简单、安全,产物的产率高、结构单一,便于分离和提纯,污染小。
具体实施方式
为了更好地理解本发明,下面结合实施例进一步清楚阐述本发明的内容,但本发明的保护内容不仅仅局限于下面的实施例。在下文的描述中,给出了大量具体的细节以便提供对本发明更为彻底的理解。然而,对于本领域技术人员来说显而易见的是,本发明可以无需一个或多个这些细节而得以实施。在其他的例子中,为了避免与本发明发生混淆,对于本领域公知的一些技术特征未进行描述。
下述实施例中,HOTf表示三氟甲磺酸,为其英文缩写。
实施例1
2,6-二苯基-4-对甲基吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),对甲基苄胺0.75mmol(91.6mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率92%,纯度为99.9%。1HNMR(400MHz,DMSO-d 6)δppm:δ8.33(d,J=7.2Hz,4H),8.18(s,2H),7.96(d,J=8.4Hz,2H),7.49-7.58(m,6H),7.38(d,J=8.0Hz,2H);13CNMR(100MHz,DMSO-d 6)δppm:δ156.4,149.9,139.5,139.3,135.2,130.2,129.7,129.2,127.6,127.4,116.7,21.3;HRMS(EI)Calcd.forC24H19N:[M+],321.1517.Found:m/z321.1521.
实施例2
4-(4-氟苯基)-2,6-二苯基吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),对氟苄胺0.75mmol(93.8mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率78%,纯度为99.8%1HNMR(400MHz,DMSO-d 6)δppm:δ8.36(d,J=7.6Hz,4H),8.21(s,2H),8.15(q,2H),7.49-7.60(m,6H),7.43(t,2H);13CNMR(100MHz,DMSO-d 6)δppm:δ164.7,162.2,157.0,148.9,139.2,134.6,130.1,129.7,129.2,127.4,116.5;HRMS(EI)Calcd.forC23H16NF:[M+],325.1267.Found:m/z325.1268.
实施例3
2,6-二苯基-4-间甲基吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),间甲基苄胺0.75mmol(91.6mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率91%,纯度为99.9%。1HNMR(400MHz,CDCl3)δppm:δ8.22(d,J=7.6Hz,4H),7.87(q,2H),7.41-7.55(m,9H),7.29(s,1H);13CNMR(100MHz,CDCl3)δppm:δ157.5,150.4,139.7,139.1,138.9,129.8,129.1,128.8,128.0,127.2,127.2,124.4,117.2,21.6;HRMS(EI)Calcd.forC24H19N:[M+],321.1517.Found:m/z321.1519.
实施例4
4-(3-氟苯基)-2,6-二苯基吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),间氟苄胺0.75mmol(93.8mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率87%,纯度为99.5%。1HNMR(400MHz,DMSO-d 6)δppm:δ8.35(d,J=7.6Hz,4H),8.24(s,2H),7.91-8.00(m,2H),7.47-7.58(m,8H);13CNMR(100MHz,DMSO-d 6)δppm:δ164.5,162.0,157.1,148.6,139.1,131.5,129.8,129.2,129.1,128.4,128.1,127.5,117.1;HRMS(EI)Calcd.forC23H16NF:[M+],325.1267.Found:m/z325.1270.
实施例5
2,6-苯基-4-(2-噻吩基)吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),2-噻吩甲胺0.75mmol(84.9mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率89%,纯度为99.7%。1HNMR(400MHz,DMSO-d 6)δppm:δ8.29(d,J=7.2Hz,4H),8.12(s,2H),8.09-8.11(q,1H),7.91-8.00(m,2H),7.78–7.80(m,2H),7.48-7.58(m,6H),7.28-7.30(m,1H),13CNMR(100MHz,DMSO-d 6)δppm:δ157.2,143.5,141.2,138.9,129.9,129.3,129.3,128.8,127.6,127.3,115.1;HRMS(EI)Calcd.forC21H15NS:[M+],313.0925.Found:m/z313.0926.
实施例6
4-苄基-2,6-二苯基吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),2-苯基乙胺0.75mmol(90.9mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率84%,纯度为99.6%。1HNMR(400MHz,CDCl3)δppm:δ8.09(d,J=7.2Hz,4H),7.42-7.48(m,6H),7.35-7.39(m,2H),7.19-7.31(m,5H),4.01(s,2H);13CNMR(100MHz,CDCl3)δppm:δ157.2,151.4,139.3,139.3,129.2,129.1,128.9,128.8,127.2,126.8,119.5,41.8;HRMS(EI)Calcd.forC24H19N:[M+],321.1517.Found:m/z321.1519.
实施例7
4-戊基-2,6-二苯基吡啶的制备:在反应容器中加入苯乙酮1mmol(120mg),正己胺0.75mmol(75.9mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率87%,纯度为99.7%。1HNMR(400MHz,CDCl3)δppm:δ8.14(d,J=7.2Hz,4H),7.39-7.51(m,8H),2.69-2.73(q,2H),1.68-1.73(m,2H),1.32-1.37(m,4H),0.89-0.92(q,3H);13CNMR(100MHz,CDCl3)δppm:δ156.9,153.2,139.8,128.8,128.7,127.1,119.1,35.8,31.5,30.3,22.6,14.1;HRMS(EI)Calcd.forC22H23N:[M+],301.1830.Found:m/z301.1833.
实施例8
4-戊基-2,6-二对甲苯基吡啶的制备:在反应容器中加入对甲基苯乙酮1mmol(134.2mg),正己胺0.75mmol(75.9mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率90%,纯度为99.9%。1HNMR(400MHz,CDCl3)δppm:δ7.96(d,J=8.0Hz,4H),7.78(s,2H),7.20(d,J=8.0Hz,4H),2.59-2.63(q,2H),2.33(s,6H),1.61-1.65(m,2H),1.28-1.29(m,4H),0.81-0.84(q,3H);13CNMR(100MHz,CDCl3)δppm:δ156.8,153.0,138.7,137.1,129.3,126.9,118.5,35.8,31.5,30.3,22.6,21.3,14.0;HRMS(EI)Calcd.forC24H27N:[M+],329.2143.Found:m/z329.2145.
实施例9
4-戊基-2,6-二间甲苯基吡啶的制备:在反应容器中加入间甲基苯乙酮1mmol(134.2mg),正己胺0.75mmol(75.9mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率88%,纯度为99.7%。(3j):1HNMR(400MHz,CDCl3)δppm:δ7.72-7.93(m,4H),7.39(s,2H),7.26-7.33(m,2H),7.13(d,J=6.8Hz,2H),2.59-2.63(q,2H),2.37(s,6H),1.61-1.64(m,2H),1.27-1.33(m,4H),0.81-0.85(q,3H);13CNMR(100MHz,CDCl3)δppm:δ157.1,153.1,139.9,138.2,129.6,128.6,127.8,124.3,119.2,35.8,31.6,30.4,22.6,21.7,14.1;HRMS(EI)Calcd.forC24H27N:[M+],329.2143.Found:m/z329.2144.
实施例10
4-苯基-2,6-二-(2-噻吩基)吡啶的制备:在反应容器中加入2-乙酰基噻吩1mmol(126.2mg),苄胺0.75mmol(80.4mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率77%,纯度为99.5%。1HNMR(400MHz,CDCl3)δppm:δ7.62-7.66(m,6H),7.38-7.49(m,5H),7.08-7.11(t,2H),;13CNMR(100MHz,CDCl3)δppm:152.7,150.2,144.9,138.6,129.2,129.2,128.0,127.9,127.1,124.9,115.1;HRMS(EI)Calcd.forC19H13NS2:[M+],319.0489.Found:m/z319.0484.
实施例11
2,6-二-(2-苯并呋喃)-4-苯基吡啶的制备:在反应容器中加入2-乙酰基苯并呋喃1mmol(160.2mg),苄胺0.75mmol(80.4mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率84%,纯度为99.6%。1HNMR(400MHz,CDCl3)δppm:δ8.08(s,2H),7.84(d,J=7.2Hz,2H),7.69(d,J=7.6Hz,2H),7.64(s,2H),7.48-7.60(m,5H),7.34(t,2H),7.29(t,2H);13CNMR(100MHz,CDCl3)δppm:δ155.4,155.2,150.1,149.9,138.1,129.4,129.2,128.9,127.2,125.3,123.3,121.8,116.8,111.6,105.5;HRMS(EI)Calcd.forC27H17NO2:[M+],387.1259.Found:m/z387.1265.
实施例12
2,6-二-(2-萘基)-4-对甲苯基吡啶的制备:在反应容器中加入2-萘乙酮1mmol(170mg),对甲基苄胺0.75mmol(91.6mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=40:1(v/v),得到白色固体产品,产率82%,纯度为99.9%。1HNMR(400MHz,CDCl3)δppm:δ8.64(s,2H),8.37(d,J=8.4Hz,2H),7.95-7.98(m,6H),7.87(d,J=8.4Hz,2H),7.66(d,J=7.6Hz,2H),7.50(m,4H),7.31(d,J=7.6Hz,2H),2.41(s,3H);13CNMR(100MHz,CDCl3)δppm:δ157.5,150.2,139.2,137.1,136.1,133.9,133.6,129.9,128.9,128.5,127.8,127.1,126.6,126.3,125.1,117.3,21.4;HRMS(EI)Calcd.forC32H23N:[M+],421.1830.Found:m/z421.1832.
实施例13
4-(4-氟苯基)-2,6-二-(2-萘基)吡啶的制备:在反应容器中加入2-萘乙酮1mmol(170mg),对氟苄胺0.75mmol(93.8mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=40:1(v/v),得到白色固体产品,产率78%,纯度为99.7%。1HNMR(400MHz,DMSO-d 6)δppm:δ8.96(s,2H),8.59(dd,J=8.4,0.8Hz,2H),8.41(s,2H),8.20-8.22(m,2H),8.10-8.15(m,4H),8.00-8.02(m,2H),7.57-7.63(m,4H),7.44-7.57(t,2H);13CNMR(100MHz,DMSO-d 6)δppm:δ150.7,149.1,136.6,134.6,133.9,133.6,130.2,130.1,129.2,128.7,128.1,127.3,127.0,126.8,125.3,116.4;HRMS(EI)Calcd.forC31H20NF:[M+],425.1580.Found:m/z425.1583.
实施例14:2,6-二-(4-氯苯基)-4-苯基吡啶的制备:在反应容器中加入对氯苯乙酮1mmol(154.6mg),苄胺0.75mmol(80.4mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率87%,纯度为99.7%。1HNMR(400MHz,DMSO-d 6)δppm:δ8.16(d,J=7.6Hz,4H),7.90(s,2H),7.76(d,J=6.4Hz,2H),7.47-7.55(m,7H);13CNMR(100MHz,DMSO-d 6)δppm:δ160.9,155.3,143.2,142.5,139.8,134.0,134.0,133.6,133.1,131.9,121.8;HRMS(EI)Calcd.forC23H15NCl2:[M+],375.0582.Found:m/z375.0786.
实施例15
4-苯基-2,6-二对甲苯基吡啶的制备:在反应容器中加入对甲基苯乙酮1mmol(134.2mg),苄胺0.75mmol(80.4mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率91%,纯度为99.9%。1HNMR(400MHz,CDCl3)δppm:δ8.08(d,J=8.0Hz,4H),7.81(s,2H),7.71(d,J=7.2Hz,2H),7.44-7.51(m,3H),7.29(d,J=8.0Hz,4H),2.40(s,6H);13CNMR(100MHz,CDCl3)δppm:δ152.7,145.3,134.6,134.2,132.2,124.7,124.4,124.1,122.5,122.3,111.8,16.6;HRMS(EI)Calcd.forC25H21N:[M+],335.1674.Found:m/z335.1679.
实施例16
2,4,6-对甲苯基吡啶的制备:在反应容器中加入对甲基苯乙酮1mmol(134.2mg),对甲基苄胺0.75mmol(91.6mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率95%,纯度为99.8%。1HNMR(400MHz,CDCl3)δppm:δ8.09(d,J=7.6Hz,4H),7.81(s,2H),7.63(d,J=7.2Hz,2H),7.30(d,J=6.4Hz,6H),2.42(s,6H);13CNMR(100MHz,CDCl3)δppm:δ157.4,149.9,138.9,137.0,129.8,129.4,127.0,116.3,21.3;HRMS(EI)Calcd.forC26H23N:[M+],349.1834.Found:m/z349.1830.
实施例17
4-(4-氟苯基)-2,6-二对甲苯基吡啶的制备:在反应容器中加入对甲基苯乙酮1mmol(134.2mg),对氟苄胺0.75mmol(93.8mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率87%,纯度为99.5%。1HNMR(400MHz,CDCl3)δppm:δ8.08(d,J=8.0Hz,4H),7.78(s,2H),7.69-7.73(t,2H),7.31(d,J=8.0Hz,2H),7.19-7.25(m,4H),2.43(s,6H);13CNMR(100MHz,CDCl3)δppm:δ164.6,162.1,157.5,149.0,139.1,136.8,129.4,129.0,128.9,127.0,116.0,21.4;HRMS(EI)Calcd.forC25H20NF:[M+],353.1580.Found:m/z353.1582.
实施例18
2,4,6-三间甲基吡啶的制备:在反应容器中加入间甲基苯乙酮1mmol(134.2mg),间甲基苄胺0.75mmol(91.6mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率89%,纯度为99.7%。1HNMR(400MHz,CDCl3)δppm:δ7.79–8.01(m,4H),7.85(s,2H),7.56(s,2H),7.39-7.43(m,3H),7.25-7.29(m,3H),2.48(s,9H);13CNMR(100MHz,CDCl3)δppm:δ157.7,150.2,139.7,139.1,138.8,138.3,129.8,129.7,129.0,128.6,127.9,127.9,124.4,117.3,21.7,21.6;HRMS(EI)Calcd.forC26H23N:[M+],349.1830.Found:m/z349.1833.
实施例19
4-(间氟苯基)-2,6-二间甲苯基吡啶的制备:在反应容器中加入间甲基苯乙酮1mmol(134.2mg),间氟苄胺0.75mmol(93.8mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率85%,纯度为99.9%。1HNMR(400MHz,CDCl3)δppm:δ7.97(m,4H),7.80(s,2H),7.38=7.52(m,5H),7.26(d,J=7.6Hz,2H),7.13-7.17(t,1H),2.47(s,6H);13CNMR(100MHz,CDCl3)δppm:δ164.5,162.1,157.9,148.8,139.4,138.4,130.7,130.0,128.7,127.9,124.4,122.9,116.6,21.7;HRMS(EI)Calcd.forC25H20NF:[M+],353.1580.Found:m/z353.1581.
实施例20
在反应容器中加入苯乙酮1mmol(120mg),苄胺0.75mmol(80.4mg),催化剂HOTf0.05mmol(7.5mg)。在120℃油浴中反应24小时,冷却至室温,加水淬灭反应,用乙酸乙酯洗涤三次,分液,合并有机层,活性炭脱色,过滤,无水硫酸钠干燥,减压浓缩,产品经过柱层析纯化,洗脱剂为石油醚:乙酸乙酯=50:1(v/v),得到白色固体产品,产率87%,纯度为99.7%。1HNMR(500MHz,CDCl3)ppm:8.43(d,J=8.0Hz,1H),8.34(d,J=8.0Hz,2H),8.00(d,J=8.5Hz,1H),7.92(s,1H),7.80(t,1H),7.51-7.64(m,9H);13CNMR(500MHz,CDCl3):156.90,149.23,149.05,139.77,138.56,130.35,129.70,129.60,129.50,128.96,128.72,128.52,127.75,126.47,125.92,125.75,119.39;HRMS(EI)Calcd.forC21H15N:[M+],281.1207;Found:281.1204。

Claims (6)

1.一种合成三取代吡啶衍生物的方法,在三氟甲磺酸的存在下,其特征在于:由式Ⅰ所示的胺化合物和式Ⅱ所示的酮化合物反应合成式Ⅲ所示的吡啶衍生物,
式Ⅰ:;式Ⅱ:;式Ⅲ:
其中,
R1选自苯基、甲苯基、噻吩基、苯甲基、C1-C7烷基中的一种,其中,R1取代基中的苯基、甲苯基、噻吩基、苯甲基、C1-C7烷基中的任何CH、CH2或CH3基团任选在所述CH、CH2或CH3基团上带有1、2或3个可相同或不同的以下的取代基:卤素或硝基;
R2选自苯基、甲苯基、噻吩基、苯并呋喃基、萘基中的一种,其中,R2取代基中的苯基、甲苯基、噻吩基、苯并呋喃基、萘基中的任何CH、CH2或CH3基团任选在所述CH、CH2或CH3基团上带有1、2或3个可相同或不同的以下的取代基:卤素或硝基;
卤素为氟、氯、溴或碘的取代基。
2.如权利要求1所述的合成三取代吡啶衍生物的方法,其特征在于:所述式Ⅰ所示的胺化合物为苄胺、对甲基苄胺、对氟苄胺、间甲基苄胺、间氟苄胺、2-噻吩甲胺、2-苯基乙胺或正己胺。
3.如权利要求1所述的合成三取代吡啶衍生物的方法,其特征在于:所述式Ⅱ所示的酮化合物为苯乙酮、对甲基苯乙酮、间甲基苯乙酮、2-乙酰基噻吩、2-乙酰基苯并呋喃、2-萘乙酮或对氯苯乙酮。
4.如权利要求1所述的合成三取代吡啶衍生物的方法,其特征在于:所述式Ⅲ所示的吡啶衍生物为2,6-二苯基-4-对甲基吡啶、4-(4-氟苯基)-2,6-二苯基吡啶、2,6-二苯基-4-间甲基吡啶、4-(3-氟苯基)-2,6-二苯基吡啶、2,6-苯基-4-(2-噻吩基)吡啶、4-苄基-2,6-二苯基吡啶、4-戊基-2,6-二苯基吡啶、4-戊基-2,6-二对甲苯基吡啶、4-戊基-2,6-二间甲苯基吡啶、4-苯基-2,6-二-(2-噻吩基)吡啶、2,6-二-(2-苯并呋喃)-4-苯基吡啶、2,6-二-(2-萘基)-4-对甲苯基吡啶、4-(4-氟苯基)-2,6-二-(2-萘基)吡啶、2,6-二-(4-氯苯基)-4-苯基吡啶、4-苯基-2,6-二对甲苯基吡啶、2,4,6-对甲苯基吡啶、4-(4-氟苯基)-2,6-二对甲苯基吡啶、2,4,6-三间甲基吡啶或4-(间氟苯基)-2,6-二间甲苯基吡啶。
5.如权利要求1所述的合成三取代吡啶衍生物的方法,其特征在于,所述合成三取代吡啶衍生物的方法,具体步骤如下:在反应容器中依次加入摩尔比为4:3的式Ⅰ所示的酮化合物和式Ⅱ所示的胺化合物,接着加入催化剂三氟甲磺酸,所述催化剂的加入量为0.05mmol/mmol酮化合物,在115~125℃油浴中反应18~24小时,冷却至室温,加水淬灭反应,萃取,减压浓缩,经柱层析纯化,得到三取代吡啶衍生物产品。
6.如权利要求5所述的合成三取代吡啶衍生物的方法,其特征在于,所述柱层析纯化的条件为:洗脱剂为石油醚和乙酸乙酯的混合物,石油醚和乙酸乙酯的体积比为50:1。
CN201510699625.6A 2015-10-26 2015-10-26 一种合成三取代吡啶衍生物的方法 Active CN105237466B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510699625.6A CN105237466B (zh) 2015-10-26 2015-10-26 一种合成三取代吡啶衍生物的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510699625.6A CN105237466B (zh) 2015-10-26 2015-10-26 一种合成三取代吡啶衍生物的方法

Publications (2)

Publication Number Publication Date
CN105237466A true CN105237466A (zh) 2016-01-13
CN105237466B CN105237466B (zh) 2017-08-25

Family

ID=55035338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510699625.6A Active CN105237466B (zh) 2015-10-26 2015-10-26 一种合成三取代吡啶衍生物的方法

Country Status (1)

Country Link
CN (1) CN105237466B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646335A (zh) * 2016-03-16 2016-06-08 中国药科大学 一种2,4,6-三取代吡啶及稠环吡啶-2酮类化合物的合成方法
CN106336375A (zh) * 2016-08-02 2017-01-18 四川大学 一种吡啶类化合物双碳氢活化芳基化的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027604A1 (fr) * 1993-05-28 1994-12-08 Taisho Pharmaceutical Co., Ltd. Utilisation medicale d'un derive de pyridine
US20140179878A1 (en) * 2012-12-25 2014-06-26 Taiwan Textile Research Institute Dinitro monomer, diamine monomer, polyimide and modified polyimide
CN104557684A (zh) * 2013-10-09 2015-04-29 郁建涵 制备3-氯-2-氨甲基-5-三氟甲基吡啶的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027604A1 (fr) * 1993-05-28 1994-12-08 Taisho Pharmaceutical Co., Ltd. Utilisation medicale d'un derive de pyridine
US20140179878A1 (en) * 2012-12-25 2014-06-26 Taiwan Textile Research Institute Dinitro monomer, diamine monomer, polyimide and modified polyimide
CN104557684A (zh) * 2013-10-09 2015-04-29 郁建涵 制备3-氯-2-氨甲基-5-三氟甲基吡啶的方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ABOLGHASEM DAVOODNIA等: "Highly efficient, one-pot, solvent-free synthesis of 2,4,6-triarylpyridines using a Bronsted-acidic ionic liquid as reusable catalyst", 《MONATSH CHEM》 *
HUAWEN HUANG等: "Copper-Catalyzed Formal C-N Bond Cleavage of Aromatic Methylamines: Assembly of Pyridine Derivatives", 《THE JOURNAL OF ORGANIC CHEMISTRY》 *
JINHAI SHEN等: "Base-Promoted β-C(sp3)-H Functionalization of Enaminones: An Approach to Polysubstituted Pyridines", 《THE JOURNAL OF ORGANIC CHEMISTRY》 *
JIN-LIN ZUO等: "2,6-Diphenylpyridine-based organic emitter for electroluminescent device", 《JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A: CHEMISTRY》 *
MAJID M. HERAVI等: "An efficient synthesis of 2,4,6-triarylpyridines catalyzed by heteropolyacid under solvent-free conditions", 《CATALYSIS COMMUNICATIONS》 *
MEHDI ADIB等: "Krohnke pyridines: an efficient solvent-free synthesis of 2,4,6-triarylpyridines", 《TETRAHEDRON LETTERS》 *
YUNHUA LU等: "Synthesis and characterization of poly(pyridine-imide)s with tert-butyl substituents", 《HIGH PERFORMANCE POLYMERS》 *
余富朝,等: "无溶剂反应在杂环合成中的应用进展", 《有机化学》 *
吴晓进: "含氮杂环化合物的合成", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 *
吴萍,等: "2,4,6-三芳基吡啶的微波辐射促进合成", 《应用化学》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646335A (zh) * 2016-03-16 2016-06-08 中国药科大学 一种2,4,6-三取代吡啶及稠环吡啶-2酮类化合物的合成方法
CN106336375A (zh) * 2016-08-02 2017-01-18 四川大学 一种吡啶类化合物双碳氢活化芳基化的方法
CN106336375B (zh) * 2016-08-02 2019-02-15 四川大学 一种吡啶类化合物双碳氢活化芳基化的方法

Also Published As

Publication number Publication date
CN105237466B (zh) 2017-08-25

Similar Documents

Publication Publication Date Title
Xiang et al. Synthesis of β-ketophosphonates via AgNO3-catalyzed hydration of alkynylphosphonates: a rate-enhancement effect of methanol
CN102827042B (zh) 氟苯尼考的手性合成方法
CN105801575B (zh) 一种咪唑并[1,2-a]吡啶的合成方法
CN110668913B (zh) 一种三氟乙基类化合物的制备方法
CN104327008A (zh) 一种苯并噁唑类化合物的合成方法
CN110183378B (zh) 一种烟酰胺的衍生物及其催化合成方法
CN105175328A (zh) 一种利用芳香胺、芳香醛、酮合成喹啉衍生物的方法
CN110204487A (zh) 一种喹啉衍生物的合成方法
CN104803964A (zh) 多取代异香豆素衍生物及其制备方法
CN110452141B (zh) 一种无过渡金属催化合成二芳基硫醚类化合物的方法
CN109293491B (zh) 一种芳基重氮盐脱重氮上酰基的方法
CN105237466A (zh) 一种合成三取代吡啶衍生物的方法
CN109836457B (zh) 一种高位阻手性p,n,n配体及其制备方法和应用
CN106543081B (zh) 一种1-二氟烷基异喹啉的制备方法
CN109896944B (zh) 一种合成1,4-萘醌并环丙烷类化合物的方法
CN101812022B (zh) 芳基嘧啶的邻位单乙酰氧基取代化合物及其方法
CN104945434B (zh) (2﹣二取代膦苯基)-1-烷基-吲哚膦配体及其合成方法和应用
CN106045952A (zh) 一种含砜基的苯并呋喃酮化合物的合成方法
CN110078661B (zh) 一种3-烯基-2,2′-联吡啶-6-甲酰胺衍生物的制备方法
CN108383779B (zh) 一种3′-芳基-2,2′-联吡啶-6-甲酰胺衍生物的制备方法
CN108690018B (zh) 一种咪唑并[1,2-a]吡啶衍生物的制备方法
CN110746336B (zh) 一种n-甲基-2-氰基-3-芳基吡咯化合物的绿色制备方法
CN105153003A (zh) 一种三氟甲基硒代炔类化合物的合成方法
CN105198806A (zh) 一种利用芳香胺、二酮合成喹啉衍生物的方法
CN102070420B (zh) 一种2-溴-6-氟苯甲醛的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20181128

Address after: 473000 Longfeng Road 369, Wolong District, Nanyang City, Henan Province

Patentee after: Nanyang de st Digital Technology Co., Ltd.

Address before: 473061 No. 1638 Wolong Road, Nanyang City, Henan Province

Patentee before: Nanyang Normal College